Eterna Therapeutics
ERNA
9 hedge funds and large institutions have $5.36M invested in Eterna Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
7,106% more capital inflows, than outflows
Capital inflows: $648K | Capital outflows: $9K
13% more funds holding
Funds holding: 8 → 9 (+1)
2.27% more ownership
Funds ownership: 29.13% → 31.41% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
North Star Investment Management
Chicago,
Illinois
|
+$432K |
| 2 |
Renaissance Technologies
New York
|
+$108K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9K |
ERNA Hedge Fund Activity: Q2 2017 in Review
9 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2017, worth a combined $5.36M — down 14% from $6.21M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ERNA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was North Star Investment Management, adding an estimated $432K. The largest seller was Deutsche Bank, cutting an estimated $9K.
- 9 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2017, up from 8 in Q1 2017.
- Funds reported $5.36M of Eterna Therapeutics stock for Q2 2017, down 14% quarter-over-quarter.
- 1 fund opened new Eterna Therapeutics positions in Q2 2017 and 0 closed out, a net change of +1 holder.
- The largest Eterna Therapeutics buyer in Q2 2017 was North Star Investment Management, an estimated $432K added.
- The largest Eterna Therapeutics seller in Q2 2017 was Deutsche Bank, an estimated $9K sold.
Based on aggregated 13F filings for Q2 2017.